Denis Raccah1, Jay Lin2, Edward Wang3, Maeva Germé4, Riccardo Perfetti4, Riccardo C Bonadonna5, Pedro de Pablos-Velasco6, Ronan Roussel7, Julio Rosenstock8. 1. University Hospital Sainte Marguerite, Marseille, France. Electronic address: denis.raccah@ap-hm.fr. 2. Outcomes Research, Novosys Health, Flemington, NJ, USA. 3. Diabetes-Metabolism Franchise, Sanofi-Aventis US, Bridgewater, NJ, USA. 4. Diabetes-Metabolism Franchise, Sanofi, Paris, France. 5. University of Verona Medical School and Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy. 6. Dr Negrin Hospital, Las Palmas University, Las Palmas, Spain. 7. Department of Diabetology, Endocrinology and Nutrition, Assistance Publique Hôpitaux de Paris, Bichat Hospital, Paris, France; INSERM, Research Unit 872, Paris, France; University Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, Paris, France. 8. Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA.
Abstract
AIMS: To compare the efficacy and safety of lixisenatide (LIXI), a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist, as add-on to basal insulin (Basal+LIXI) versus once-daily rapid-acting insulin (Basal+RAI) in patients with type 2 diabetes mellitus (T2DM). METHODS: Data were extracted from five randomized controlled trials assessing the efficacy and safety of basal insulin+insulin glulisine (n=3) or basal insulin+LIXI (n=2). Patients in the Basal+LIXI cohort were matched to patients in the Basal+RAI cohort using propensity score matching. RESULTS: In the matched population, Basal+LIXI was twice as likely to reach composite outcomes of glycated haemoglobin (HbA1c) <7% and no symptomatic hypoglycaemia compared with the Basal+RAI group (odds ratio [OR]: 1.90; 95% confidence interval [CI]: 1.01, 3.55; P=0.0455), as well as HbA1c <7% and no severe hypoglycaemia (OR: 1.97; 95 CI: 1.06, 3.66; P=0.0311). Furthermore, Basal+LIXI was more than twice as likely to reach HbA1c <7%, no weight gain and no symptomatic hypoglycaemia (OR: 2.58; 95% CI: 1.23, 5.40; P=0.0119). CONCLUSIONS: Both basal+LIXI and Basal+RAI improved glycaemic control in patients with T2DM with inadequate glycaemic control on basal insulin. Basal+LIXI offers an effective therapeutic option to advance basal insulin therapy, improving glucose control without weight gain and with less risk of hypoglycaemia than prandial insulin.
AIMS: To compare the efficacy and safety of lixisenatide (LIXI), a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist, as add-on to basal insulin (Basal+LIXI) versus once-daily rapid-acting insulin (Basal+RAI) in patients with type 2 diabetes mellitus (T2DM). METHODS: Data were extracted from five randomized controlled trials assessing the efficacy and safety of basal insulin+insulinglulisine (n=3) or basal insulin+LIXI (n=2). Patients in the Basal+LIXI cohort were matched to patients in the Basal+RAI cohort using propensity score matching. RESULTS: In the matched population, Basal+LIXI was twice as likely to reach composite outcomes of glycated haemoglobin (HbA1c) <7% and no symptomatic hypoglycaemia compared with the Basal+RAI group (odds ratio [OR]: 1.90; 95% confidence interval [CI]: 1.01, 3.55; P=0.0455), as well as HbA1c <7% and no severe hypoglycaemia (OR: 1.97; 95 CI: 1.06, 3.66; P=0.0311). Furthermore, Basal+LIXI was more than twice as likely to reach HbA1c <7%, no weight gain and no symptomatic hypoglycaemia (OR: 2.58; 95% CI: 1.23, 5.40; P=0.0119). CONCLUSIONS: Both basal+LIXI and Basal+RAI improved glycaemic control in patients with T2DM with inadequate glycaemic control on basal insulin. Basal+LIXI offers an effective therapeutic option to advance basal insulin therapy, improving glucose control without weight gain and with less risk of hypoglycaemia than prandial insulin.
Authors: Melanie J Davies; Lawrence A Leiter; Bruno Guerci; George Grunberger; F Javier Ampudia-Blasco; Christine Yu; William Stager; Elisabeth Niemoeller; Elisabeth Souhami; Julio Rosenstock Journal: Diabetes Obes Metab Date: 2017-07-07 Impact factor: 6.577
Authors: Diego Bellido; Pablo Abellán; José Manuel Ruiz Palomar; Rogelio Álvarez Sintes; Andreu Nubiolae; Virginia Bellido; Gracia Romero Journal: Curr Ther Res Clin Exp Date: 2018-10-09